Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nippon Shinyaku Launches Orally Disintegrating Gaslon Tablets To Prolong Drug Lifecycle

This article was originally published in PharmAsia News

Executive Summary

To prolong the lifecycle of gastritis and ulcer drug Gaslon (irsogladine), Nippon Shinyaku will launch an orally disintegrating tablet next November. company president Shigenobu Maekawa announced Nov.12. Maekawa said the company is also considering OD tablets for other drugs. Nippon Shinyaku has set three growth strategies: prolonging the lifecycle for current products, licensing products from others and in-house new drug development. This July, the company launched an OD tablet for benign prostatic hyperplasia drug Eviprostat (herbal extract) and saw sales for the new product grow 10 percent. Dysmenorrhea drugLunabell (norethisterone) was licensed and launched this July, and the company expects it to achieve ¥1 billion in sales by March 2009. (Click here for more - Japanese language

You may also be interested in...

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

International Harmonization: Not Just For Audits Anymore

The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.

Reddy’s Settles On $7bn Revlimid But Natco Maintains The Lead

Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts